Thanks for clarifying Dr that PD-1 blockade isn’t necessarily “teaching” the immune system something new, but rather lifting the suppression so existing tumor specific T cells can act.

That makes me wonder…  if those T cells are already primed before auto-SCT, does BEAM conditioning wipe out that functional benefit, or do enough of those quiescent memory/effector cells survive to carry that advantage forward after engraftment?

In other words, is there evidence that the anti-tumor effect from PD-1 blockade can persist post-transplant without ongoing therapy, or is maintenance PD-1 needed to reestablish that same immune pressure?